GENELINK, INC. AND SUBSIDIARY

		(Unaudited)
		September 30, 2007				December 31, 2006
ASSETS
Current Assets
Cash		$	44,760			$	149,695
Accounts receivable			31,943				32,185
Inventory			4,156				5,772
Prepaid expenses			11,273				14,421
Total current assets			92,132				202,073
Property and equipment			110,281				131,645
Other assets			377,595				380,675
Total assets		$	580,008			$	714,393
LIABILITIES
Current liabilities
Accounts payable and accrued expenses		$	447,430			$	365,590
Deferred revenue			3,265				15,481
Loans payable			118,000				18,000
Total current liabilities			568,695				399,071
Convertible secured promissory notes payable			828,812				622,890
Accrued compensation			144,168				710,323
Total liabilities			1,541,675				1,732,284
STOCKHOLDERS’ EQUITY (DEFICIT)
Common stock, par value $0.01 per share; authorized: 125,000,000 shares and 75,000,000 as of September 30, 2007 and December 31, 2006, respectively; issued: 45,425,863 and 41,738,988 shares as of September 30, 2007 and December 31, 2006, respectively; outstanding: 45,019,682 and 41,332,814 shares as of September 30, 2007 and December 31, 2006, respectively			454,259				417,390
Additional paid-in capital			7,611,291				6,982,849
Stock warrants			3,537,659				3,011,009
Accumulated deficit			(12,249,821	)			(11,114,084	)
Treasury stock, 406,169 shares as of September 30, 2007 and December 31, 2006, at cost			(315,055	)			(315,055	)
Total shareholders’ equity (deficiency)			(961,667	)			(1,017,891	)
Total liabilities and shareholders’ equity (deficiency)		$	580,008			$	714,393

The accompanying notes are an integral part of the consolidated financial statements

GENELINK, INC. AND SUBSIDIARY

Three months ended September 30,		2007				2006
REVENUE		$	26,150			$	59,122
COST OF GOODS SOLD			11,608				25,916
GROSS PROFIT			14,542				33,206
EXPENSES
Selling, general and administrative			78,386				91,892
Fair value of options and warrants granted			363,400				0
Consulting			21,000				34,265
Professional fees			44,901				14,803
Advertising and promotion			1,580				1,450
Interest expense			41,847				20,701
Amortization and depreciation			14,175				8,793
			565,289				171,904
NET LOSS BEFORE PROVISION FOR INCOME TAXES			(550,747	)			(138,698	)
PROVISIONS FOR INCOME TAXES			0				0
NET LOSS		$	(550,747	)		$	(138,698	)
NET LOSS PER SHARE BASIC AND DILUTED		$	(0.01	)		$	(0.003	)
Weighted average common shares and diluted potential common shares			45,307,320				39,923,988

The accompanying notes are an integral part of the consolidated financial statements.

GENELINK, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

Nine months ended September 30,		2007				2006
REVENUE		$	85,216			$	142,458
COST OF GOODS SOLD			57,478				53,643
GROSS PROFIT			27,738				88,815
EXPENSES
Selling, general and administrative			266,697				296,942
Fair value of options and warrants granted			363,400				0
Consulting			88,648				138,989
Professional fees			266,221				155,895
Advertising and promotion			6,476				4,317
Interest expense			129,510				66,028
Amortization and depreciation			42,522				34,608
			1,163,474				696,779
NET LOSS BEFORE PROVISION FOR INCOME TAXES			(1,135,736	)			(607,964	)
PROVISION FOR INCOME TAXES			0				0
NET LOSS		$	(1,135,736	)		$	(607,964	)
NET LOSS PER SHARE BASIC AND DILUTED		$	(0.02	)		$	(0.02	)
Weighted average common shares and diluted potential common shares			43,890,272				38,073,769

The accompanying notes are an integral part of the consolidated financial statements.

GENELINK, INC. AND SUBSIDIARY

Nine months ended September 30,		2007				2006
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		$	(1,135,736	)		$	(607,964	)
Adjustments to reconcile net loss to net cash used by operating activities
Depreciation and amortization			42,522				34,608
Amortization of discounts on loans payable			55,352				33,177
Common stock issued for services			0				24,326
Fair value of options and warrants granted			363,400				0
Changes in operating assets and liabilities
Accounts receivable			242				(1,487	)
Inventory			1,616				(3,243	)
Prepaid expenses			3,148				19,574
Other assets			0				(4,272	)
Deferred revenue			(12,216	)			22,148
Accounts payable and accrued expenses			91,792				(1,718	)
Accrued payroll taxes			0				(7,454	)
Accrued compensation			96,462				87,693
Net cash used in operating activities			(493,418	)			(404,612	)
CASH FLOWS FROM INVESTING ACTIVITIES
Capital expenditures			(6,633	)			(18,322	)
Patent acquisition costs			(37,759	)			(19,114	)
Net cash used by investing activities			(44,392	)			(37,436	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from loans and note payable			432,875				358,541
Repayment of loans and notes payable			0				(17,861	)
Proceeds relating to issuance of common stock, net			0				105,158
Net cash provided by financing activities			432,875				445,838

The accompanying notes are an integral part of the consolidated financial statements.

GENELINK, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

Nine months ended September 30,		2007				2006
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS			104,935			$	3,790
Cash and cash equivalents, beginning of period			149,695				15,275
Cash and cash equivalents, end of period			44,760			$	19,065
SUPPLEMENTARY CASH FLOW INFORMATION
Cash paid for interest		$	0			$	1,165
Non-cash financing transactions
Issuance of common stock for services		$	0			$	24,326
Stock options and warrants granted		$	363,400			$	0
Common stock and stock warrants granted for fundraising		$	12,938			$	44,100
Conversion of bridge loan and accrued interest to convertible secured loans		$	0			$	207,891
Conversion of notes payable and accrued interest to common stock		$	146,532			$	0
Stock options granted for payment of accrued compensation		$	662,617			$	0

The accompanying notes are an integral part of the consolidated financial statements.

GENELINK, INC. AND SUBSIDIARY

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1 — DESCRIPTION OF          ORGANIZATION
		Organization
		GeneLink, Inc. (the Company) and Subsidiary (Dermagenetics, inc.) operate in New Jersey. The Company was organized under the laws of the Commonwealth of Pennsylvania and Dermagenetics, Inc. was organized under the laws of the State of Delaware. The Company is the successor to a Delaware corporation organized under the same name on September 21, 1994. The Company’s offices are located in Jersey City, New Jersey.
2 — BASIS OF          PRESENTATION		The accompanying unaudited financial statements have been prepared by the Company in accordance with the instructions to Form 10-QSB and Article 10 of Regulation S-X relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements and should be read in conjunction with the financial statements and notes thereto included in the Annual Report on Form 10-KSB of GeneLink, Inc. and subsidiary for the year ended December 31, 2006.
		In the opinion of management, all adjustments (consisting of normal recurring accruals) necessary to present fairly the information set forth in the accompanying financial statements have been included. The results reported in these financial statements for the nine-month period ended September 30, 2007 should not be regarded as necessarily indicative of results that may be expected for the year ended December 31, 2007.
3 — RELATED PARTY          TRANSACTIONS AND          CONVERTIBLE          SECURED          PROMISSORY NOTES		On January 12, 2007, pursuant to the terms of a Convertible Secured Loan Agreement dated May 12, 2006 (the “Loan Agreement”), the Company issued an additional $50,000 convertible secured loan promissory note with interest accruing at 12% per annum, maturing May 12, 2011. The Company issued 250,000 shares of common stock as a condition of the Loan Agreement.
		On June 6, 2007, pursuant to the terms of a Convertible Secured Loan Agreement dated May 12, 2006 (the “Loan Agreement”), the Company issued an additional $87,000 convertible secured loan promissory note with interest accruing at 12% per annum, maturing May 12, 2011. The Company

		issued 437,500 shares of common stock as a condition of the Loan Agreement.
		The Company issued to First Equity Capital Securities, Inc., as Administrative Agent under the Loan Agreement, 68,750 shares of restricted common stock and a warrant to acquire 275,000 restricted shares of common stock at an exercise price of $.05 per share in connection with the notes. The Company also paid First Equity Capital Securities, Inc. a placement fee of 7%, or $26,600, of all loans raised in December 2006 and January 2007 in connection with the issuance of the notes.
		On January 26, 2007, two note holders converted $121,131.19 of principal and interest of convertible secured promissory notes into 2,422,625 shares of restricted common stock.
		On July 24, 2007, a noteholder converted $25,399 of principal and interest of a convertible secured promissory note into 507,988 shares of restricted common stock.
		On September 30, 2007, the Company converted $662,617 of accrued compensation owed to a Board Member into a warrant to acquire 1,400,000 shares of common stock at an exercise price of $0.11 per share.
4 — NOTE PAYABLE		The Company entered into a $100,000 loan agreement payable on August 9, 2008, with interest accruing at 12% per annum. Upon the initial closing of the Company’s equity offering on November 9, 2007, the principal amount and all accrued interest of this obligation automatically converted into the Company’s common stock and warrants upon the terms of the offering. See Note 6, “Subsequent Event”, below.
5 — STOCKHOLDER’S          EQUITY          TRANSACTIONS		On June 1, 2007 the Company granted three executives options to acquire 3,350,000 shares of common stock at an exercise price of $.08 vesting immediately, and granted, pursuant to the Company’s 2007 Option Plan, options to acquire 3,050,000 shares of common stock at an exercise price of $.08 per share vesting in four equal annual installments commencing June 1, 2007. The Company recorded compensation expense of $329,000 related to the vested options.
		On June 1, 2007, the Company granted to each member of its scientific advisory board options to acquire 140,000 shares of common stock at an exercise price of $.08 vesting immediately, and granted, pursuant to the Company’s 2007 Option Plan, options to acquire 165,000 shares of common stock at an exercise price of $.08 per share vesting in four equal annual installments commencing June 1, 2007. The Company recorded compensation expense of $24,400 related to the vested options.

		On June 1, 2007, the Company granted to each member of its board options to acquire 500,000 shares of common stock at an exercise price of $.08 vesting in four equal annual installments commencing June 1, 2007 pursuant to the Company’s 2007 Option Plan. The Company recorded compensation expense of $10,000 related to the vested options.
6 — SUBSEQUENT EVENT		On November 9 and 13, 2007, the Company sold a total of $1,165,525 of Units (each unit consisting of one share of common stock and a warrant to acquire 1/4 of one share of common stock at an exercise price of $.10 per share) at a price of $.075 per unit. This amount includes $100,000 principal amount plus accrued interest of note payable (See Note 4).
		A total of 15,540,328 shares of common stock of the Company and warrants to acquire a total of 3,885,082 shares of common stock were issued. The Company also paid a total of $101,502 and issued warrants to acquire 2,114,624 shares of common stock to advisors in connection with the Units. Included in this total is payment of $36,702 of fees and issuance of warrants to acquire 764,624 shares of common stock to First Equity Capital Securities, Inc. Kenneth R. Levine a holder of more than five percent of the equity of the Company is an officer and owner of First Equity Capital Securities. The Company will also be responsible for reimbursing out of pocket costs incurred by such advisors in an amount not to exceed 3% of the proceeds raised by such advisors.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Statements in this Report that relate to future results and events are based on the Company’s current expectations. Actual results in future periods may differ materially from those currently expected or desired because of a number of risks and uncertainties. For a discussion of factors affecting the Company’s business and prospects, see “Item 2 — Management’s Discussion and Analysis of Financial Condition and Results of Operations — Factors Affecting the Company’s Business and Prospects.”

Operating results for the nine-month period ended September 30, 2007 are not necessarily indicative of the results that may be expected for the full fiscal year ending December 31, 2007.

BUSINESS OPERATIONS AND HISTORY

The Company was founded in response to the information being generated in the field of human molecular genetics. Scientists are discovering an increasing number of connections between genes and specific diseases or physical attributes and tendencies. These findings are a direct result of the National Institute of Health Genome Project.

In May 2007, the Company received a U.S. patent: “Kits and Methods for Assessing Skin Health” for its proprietary method for assessing skin health and for the application of a therapeutic skin health regimen related to its assessment. The Company received an international patent (Australia) “Kits and Methods for Assessing Oxidative Stress” for its proprietary method of predicting oxidative (free radical) damage in humans.

The Company has developed proprietary SNP-based genetic profiles (named GeneLink Nutragenetic Profile^TM and Dermagenetics® profiles). These profiles provide a means of predicting an individual’s inherent genetic capacity to combat such conditions as oxidative stress and other important selected areas of physiologic health. The profiles, for example, can measure a person’s potential to efficiently control oxygen free radical damage, eliminate hydrogen peroxide, protect and repair oxidized phospholipids and destroy harmful environmental compounds.

The Company’s profile assessment enables nutritional and skin care companies and health care professionals to recommend a specific and targeted regime of antioxidant vitamins, nutrients or skin care formulations that have been specifically designed to compensate for predicted deficiencies and to help provide individuals the best of health and appearance.

In 2004, The Company formed a wholly owned subsidiary, Dermagenetics, Inc., to provide its genetically customized products and services to the skin and personal care market.

The Company’s Oxidative Stress (OS) Profile (US patent pending, Australian patent issued) provides a means of predicting an individual’s inherent genetic capacity to combat oxidative stress. The profile can measure a person’s potential to efficiently control oxygen free radical damage, eliminate hydrogen peroxide, protect and repair oxidized phospholipids and destroy harmful environmental compounds.

This profile information will enable nutritional and skin care companies to recommend a specific and targeted regime of antioxidant vitamins, nutrients or skin-care formulations that have been specifically designed to compensate for predicted deficiencies. Thus, the OS profile can be used

to make rational choices to help optimize nutritional and skin care needs to provide the best of health and appearance.

The Company’s Skin Health test for skin aging looks for SNPs in several key genes that are associated with oxidative stress, skin irritation, photo aging and an individual’s ability to naturally defend against environmental stresses. Skin health test results can be used to guide consumers to skin therapies or skin products containing unique active ingredients (SNPActives™) and formulations designed to help alleviate specific oxidative stress and other potential deficiencies in the skin.

The Company’s has also developed a Cardiovascular Risk Profile and an Osteopenia Susceptibility Profile.

Cardiovascular disease claims more lives each year than the next five leading causes of death combined. The Company has recently developed a Cardiovascular Risk Profile, that analyzes a broad collection of genes believed to play an important part in heart health, according to the latest research. The Company’s Cardiovascular Risk Profile is designed to identify SNPs associated with increased risk of developing high blood pressure, atherosclerosis, inflammation, problems with vascular integrity and coronary artery disease.

Osteopenia is a condition that often leads to osteoporosis, a disease characterized by low bone density. The Company’s Osteopenia gene test looks for SNPs in several key genes that are associated with bone density. Since osteoporosis can develop undetected for decades, this test may be a tool to help determine the future risk for fractures and related clinical conditions such as spinal column compression and bone breaks with or without falls and guide early interventions or therapies that help combat or prevent the condition.

The Company has developed a NQ01 SNP profile. NQ01 is a protein that contributes to the recharging Coenzyme Q10. Coenzyme Q10 is a natural compound made by the human body that helps cells produce energy and protect against free radicals that can damage DNA and other molecules of the cell. The NQ01 assessment is complete, ready to market and a provisional patent has been filed.

LIQUIDITY AND CAPITAL RESOURCES

For the nine month period ended September 30, 2007, the Company’s primary liquidity requirements have been the payment of operating expenses. In the first nine months of 2007, the Company raised $432,875 through the issuance of convertible loans.

Cash and cash equivalents at September 30, 2007 amounted to $44,760 as compared to $149,695 at December 31, 2006, a decrease of $104,935. During the first nine months of 2007, the Company’s operating activities utilized $143,418, as compared to $404,612 for the first nine months of 2006, a decrease of $261,194. Cash utilized during the nine month period ended September 30, 2007 primarily was used to fund a portion of the Company’s $143,418 of cash losses for such period.

Financing activities provided $432,875 for the nine month period ended September 30, 2007 as compared to $445,838 for the nine months ended September 30, 2006, a decrease of $12,963. Financing activities in the nine months ended September 30, 2007 resulted primarily from the issuance of convertible secured loans.

On November 9 and 13, 2007, the Company raised a total of $1,165,524.66 through the sale of common stock and warrants. The Company sold Units, at a price of $0.075 per Unit, each Unit consisting of one (1) share of common stock and a one-quarter (1/4) of a warrant to acquire one share of common stock at an exercise price of $0.10 per share. A total of 15,540,328 shares of common stock of the Company and warrants to acquire a total of 3,885,082 shares of common stock were issued. The Company also paid a total of $101,502 and issued warrants to acquire 2,114,624 shares of common stock to advisors in connection with the Units. Included in this total is payment of $36,702 of fees and issuance of warrants to acquire 764,624 shares of common stock to First Equity Capital Securities, Inc. Kenneth R. Levine a holder of more than five percent of the equity of the Company is an officer and owner of First Equity Capital Securities. The Company will also be responsible for reimbursing out of pocket costs incurred by such advisors in an amount not to exceed 3% of the proceeds raised by such advisors.

The Company intends to use the proceeds of the offering to fund, among other things: adding infrastructure to support the Company’s existing and anticipated licensing agreements; the development and pursuit of its redirected business plans, including the pursuit of new revenue producing distribution channels; the support and enhancement of the Company’s intellectual property portfolio; working capital requirements; corporate overhead, including professional fees and expenses; and the payment of outstanding payables and trade debt. The Company will require additional funds to fully fund its redirected business plan and for general working capital needs.

COMPARISON OF THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2007
TO THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2006

Financial Condition

Assets of the Company decreased from $714,393 at December 31, 2006 to $580,008 at September 30, 2007, a decrease of $134,385. This decrease was primarily due to the decrease in cash and cash equivalents of $104,935, which cash was used to partially fund cash losses for such period.

Liabilities decreased from $1,732,284 at December 31, 2006 to $1,541,675 at September 30, 2007, a decrease of $190,609. This decrease in liabilities primarily resulted from a decrease in accrued compensation payable from $710,323 as of December 31, 2006 to $144,168, a decrease of $566,155. An officer and director of the Company agreed to reduce accrued compensation due as of September 30, 2007 from $752,617 to $90,000 in exchange for certain consideration. This decrease in liabilities was partially offset by an increase in convertible secured loans payable from $622,890 at December 31, 2006 to $828,812 at September 30, 2007, an increase of $205,922, and an increase in short term loans payable from $18,000 at December 31, 2006 to $118,000 at September 30, 2007, an increase of $100,000.

Current Year Performance and Earnings Outlook

Revenues. The total revenues for the nine months ended September 30, 2007 were $85,216 as compared to $142,548 for the nine months ended September 30, 2006, a decrease of $57,332. Total revenues for the three months ended September 30, 2007 were $26,150 as compared to $59,122 for the three months ended September 30, 2006, a decrease of $32,972. Revenues decreased primarily because the Company focused on finalizing its plan to redirect its business and marketing efforts.

Expenses. Total expenses for the nine months ended September 30, 2007 were $1,163,474 as compared to $696,779 for the nine months ended September 30, 2006, an increase of $466,695, primarily resulting from the $363,400 cost for the fair value of options granted to officers, directors and consultants incurred during the nine months ended September 30, 2007. If this option cost had not been incurred, expenses for the nine month period ended September 30, 2007 would have increased only $103,295 from those incurred during the nine month period ended September 30, 2009. The increase in expenses was also partially caused by an increase in professional fees from $155,895 for the nine months ended September 30, 2006 to $266,221 for the nine months ended December 31, 2007, an increase of $110,326, primarily resulting from costs incurred in connection with the litigation brought against the Company by John R. DePhillipo, the former Chief Executive Officer and a former director of the Company.

Total expenses for the three months ended September 30, 2007 were $565,289, as compared to $171,904 for the three months ended September 30, 2006, an increase of $393,385. This increase primarily relates to the $363,400 cost for the fair value of options granted to officers, directors and consultants during such period. If this option cost had not been incurred, expenses for the three month period ended September 30, 2007 would have increased only $29,985 from those incurred during the three month period ended September 30, 2006.

Losses. The Company incurred a loss of $1,135,736 for the nine months ended September 30, 2007 as compared to a loss of $607,964 for the nine months ended September 30, 2006, an increase of $527,772. If the $363,400 cost for the fair value of options granted to officers, directors and consultants had not been incurred, the increase in losses would have been $164,372. Operating losses increased from $404,612 for the nine months ended September 30, 2006 to $493,418 for the nine months ended September 30, 2007, an increase of $88,806.

The Company incurred a loss of $550,747 for the three months ended September 30, 2007, as compared to a loss of $138,698 for the three months ended September 30, 2006, an increase of $412,049. If the $363,400 cost for the fair value of options granted to officers, directors and consultants had not been incurred, the increase in losses would have been $48,649.

FACTORS AFFECTING THE COMPANY’S BUSINESS AND PROSPECTS

There are a number of factors that affect the Company’s business and the results of its operations. These factors include general economic and business conditions; the level of acceptance of the Company’s products and services; the rate and commercial applicability of advancements and discoveries in the genetics field; the Company’s ability to enter into strategic alliances with companies in the health care, nutritional and skin-care industries; and the ability of the Company to raise the financing necessary to implement its business and marketing plan, to pay salaries to its officers and employees and to pay its accounts payable.

In July 2006, the United States Government Accountability Office (“GAO”) delivered testimony before the United States Senate Special Committee on Aging. The GAO testified that in an evaluation of genetic tests purchased from the websites of four of the Company’s competitors, the GAO determined that the tests were misleading, that they made predictions that were medically unproven and unambiguous and that did not provide meaningful information to customers. The GAO found that the recommendations were instead based upon information submitted on questionnaires accompanying the genetic tests. The GAO also found that the recommendation of costly personalized dietary supplements in connection with the test results misled consumers and could be harmful. The GAO also recommended oversight of laboratories

that perform genetic tests. The GAO included that with future advances in science, nutragenetic tests may be valid in the future.

The Company believes that its tests and products differ from those tested by the GAO in a number of ways. The Company does not currently market genetically guided nutragenetic products directly to consumers and currently does not market any nutragenetic or other nutritional products. The Company does not utilize any lifestyle type of questionnaire in making any health-related recommendations or in making any product or service recommendations. Additionally, with respect to its Dermagenetics^® line of products, the Company offers a money-back guarantee. However, the Company and its genetic tests and products may be harmed or damaged by negative publicity or market and consumer reaction to the GAO testimony and report.

ITEM 3. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

     The Company maintains disclosure controls and other procedures that are designed to ensure that information required to be disclosed in its Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

     With the participation of management, the Company’s Chief Executive Officer and Acting Chief Financial Officer evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures at the conclusion of the fiscal quarter ended September 30, 2007. Based upon this evaluation, the Chief Executive Officer and Acting Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective in ensuring that material information required to be disclosed is included in the reports that it files with the Securities and Exchange Commission.

Change In Internal Controls

There were no changes in the Company’s internal controls over financial reporting or, to the knowledge of the Company’s management, in other factors that have materially affected or are reasonably likely to materially affect internal controls over financial reporting during the fiscal quarter ended September 30, 2007.

PART II. OTHER INFORMATION

ITEM 6. Exhibits and Reports on Form 8-K.

		(a)		Exhibit No.
				31.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
				32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
		(b)		Reports on Form 8-K.
				The Company filed a Current Report on Form 8-K dated September 22, 2007 in connection with a compensation arrangement entered into with an officer and director of the Company.

* * * * * *

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

GENELINK, INC.
(Registrant)